Although RAS inhibitors have a class I indication in the latest HF guidelines [11], the same document advises using ACE inhibitors, angiotensin II receptor blockers, sacubitril/valsartan, and mineralocorticoid receptor antagonists are contraindicated or should be used with caution or seek specialist advice. This evidence concerns the gene ACE and hydrops fetalis.